Predict your next investment

Complix company logo
HEALTHCARE | Drug Development
complix.com

See what CB Insights has to offer

Stage

Grant - III | Alive

Total Raised

$29.44M

Last Raised

$590K | 4 yrs ago

About Complix

Complix is a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies, that mainly focus on oncology and autoimmune diseases. Alphabodies are a class of protein therapeutics that have the potential to address a wide range of disease targets, in particular intracellular targets that are considered undruggable by current drug formats, such as antibodies or small chemicals. Complix' R&D efforts are mainly focused on the development of Cell-Penetrating Alphabodies (CPABs) that have the capacity to enter tumor cells effectively and selectively modulate intracellular protein-to-protein interactions (PPIs) which play a key role in the initiation and progression of cancer. The company has established a strong intellectual property position protecting the Alphabody platform and its emerging product portfolio through the filing of multiple broad applications. Alphabody-based therapeutics are independent of antibody-based patent claims and offer a unique freedom-to-operate position.

Complix Headquarter Location

Agoralaan building A-bis

Diepenbeek, 3590,

Belgium

+32 (0)9 261 69 40

Latest Complix News

Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of CNS Diseases

Jul 29, 2021

Search jobs 29-Jul-2021 Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of CNS Diseases Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of CNS Diseases   Hasselt, July 28, 2021 – Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics, today announced that it has signed a global collaboration and license agreement with Jiangsu Nhwa Pharmaceutical Co., one of China’s leading CNS companies, to develop Cell Penetrating Alphabodies (CPABs), able to cross the blood brain barrier, for the improved treatment of diseases of the central nervous system (CNS). This agreement is an important corporate milestone for Complix, as it seeks to apply its industry leading CPAB platform in yet another major disease area, beyond oncology, autoimmunity, and viral diseases. Jiangsu Nhwa Pharmaceutical Co. (Nhwa) is a leading CNS company in China, which has developed an innovative and differentiated pipeline in the areas of anesthesia, analgesia, psychiatry, and neurology via both its own in-house R&D and global partnerships. Nhwa has more than 4000 employees, with capabilities in research, clinical development, manufacturing, and commercialization of CNS drugs. Complix and Nhwa will collaborate to develop novel biotherapeutics against two selected CNS targets. Complix will apply its proprietary CPAB technology, that enables biologics to traverse membrane systems and act with high affinity and precision on disease targets that are considered intractable by current drug formats. The novel compounds to be developed under this collaboration, will be designed to cross the blood brain barrier to address important disease targets in the central nervous system. Under the terms of the agreement, Complix has granted an exclusive license to Nhwa to develop, manufacture and commercialize the CPABs resulting from this collaboration in Greater China. Both companies retain joint development and commercialization rights for these CPABs in the rest of the world. Complix is entitled to upfront license payments and further milestone payments subject to the progress of clinical development and regulatory approval. Complix is also eligible for royalty payments based on the future commercial sales of the CPABs in China. Mark Vaeck, CEO of Complix, said: “We are thrilled to announce this exciting collaboration with Nhwa. We are confident that the unique targeting capabilities of our CPABs will allow us to jointly develop novel biotherapeutics that will deliver improved treatment outcomes for patients suffering from severe neurological diseases. We believe that partnering with an innovative company like Nhwa, specialized in the area of CNS diseases, is substantially value creating, as it provides access to significant research and clinical development expertise in the CNS area, as well as a strong commercial platform in China. I am confident that together we can deliver on our ambitions to develop innovative and highly needed solutions for patients with severe neurological conditions”. Jiaquan Sun, CEO of Jiangsu Nhwa added: “We are pleased to collaborate with Complix to gain access to its highly innovative CPAB platform as we look to further strengthen our position as a market leader in CNS therapies in China. We are looking forward to working with the team at Complix as we tap into their world leading intracellular targeting expertise to generate novel therapeutics that can cross the blood brain barrier to address major unmet medical needs that still exist in CNS disease area today’’. About Complix Complix is a biopharmaceutical company using its industry leading AlphabodyTM platform to develop a pipeline of transformative, “membrane crossing” therapeutics against a number of cutting-edge and challenging disease targets that play an important role in oncology, autoimmunity, CNS, and viral diseases. In addition to crossing cellular membranes, Alphabodies have the potential to cross the blood brain barrier, a critical limiting factor for other technologies aiming to address CNS disease targets. Complix is developing Cell Penetrating Alphabodies (CPABs) that can address disease targets present in the cytosol or in the nucleus of human cells and that are considered “intractable” by current drug formats, such as antibodies or small chemicals. CPABs are also equipped with half-life extension motifs, so that they stay in circulation for sufficient time to ensure optimal biodistribution to reach the cells where their target is located. As a pioneer in intracellular targeting, Complix aims to develop a pipeline of first-in-class therapeutics with the potential to cure severe diseases with high unmet medical need. The company has signed collaboration deals with I-Mab to develop novel cancer therapeutics and with Jiangsu Nhwa to develop CPABs for CNS disease. Complix has established a strong intellectual property position protecting the Alphabody platform and its emerging product portfolio through the filing of multiple patent applications. The company is led by an experienced management team with a track record of success in the biotech industry and is backed by a syndicate of experienced life sciences investors from which it has raised close to US$ 40 million. Jiangsu Nhwa Pharmaceutical Co., Ltd.  (SZ002262), founded in 1978, is a leading CNS company in China. Over the past 40 years, Nhwa has focused on developing an innovative and differentiated pipeline in the areas of anesthesia, analgesia, psychiatry, and neurology via its own in-house R&D and via global partnerships. As a fully integrated pharmaceutical company, with more than 4000 employees, Nhwa has comprehensive capabilities in research, clinical development, manufacturing, and commercialization of CNS drugs. In recent years, Nhwa has further strengthened its leadership in CNS field in China by providing precision diagnostic services for CNS disorders, as well as establishing the largest Chinese CNS internet health platform. Contacts: Tel: +32 9 261 69 40

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Complix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Complix is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,881 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Complix Patents

Complix has filed 6 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/22/2013

7/17/2018

Molecular biology, Biotechnology, Cell biology, Clusters of differentiation, Proteins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/22/2013

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/17/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, Biotechnology, Cell biology, Clusters of differentiation, Proteins

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Complix Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Complix Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.